Simo Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simo Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dong Zhao
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital Capital Medical University, Beijing, China
2 shared publications - Jing Ke
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
2 shared publications - Longyan Yang
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital Capital Medical University, Beijing, China
2 shared publications - Kun Li
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
1 shared publication - Xiaotong Feng
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
1 shared publication - Xin Wang
Institute of Medical Genomics Biomedical Sciences College Shandong First Medical University Taian Shandong China sdfmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 2431441
The Effect of Canagliflozin on High‐Density Lipoprotein Cholesterol and Angiopoietin‐Like Protein 3 in Type 2 Diabetes Mellitus
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while the results remain controversial. This study is aimed at exploring the effect of SGLT2 inhibitor canagliflozin on lipid profile. Methods. This study was a single‐center, open‐label, nonrandomized, prospective study. Metformin (500 mg three times per day) or canagliflozin (100 mg, once daily) was administered for 12 weeks. Fasting blood samples were collected before and 12 weeks after treatment. Serum lipid profile levels and angiopoietin‐like protein 3 (ANGPTL3) were determined. In animal experiment, C57BL/6 J mice were divided into three groups including control, STZ + HFD, and STZ + HFD + canagliflozin. Lipid profile and plasma ANGPTL3 level were measured after 12 week’s treatment. Moreover, the expression of ANGPTL3 was detected in the liver tissues. Results. There was a decreased trend in low‐density lipoprotein cholesterol (LDL‐c) and triglycerides (TG) after canagliflozin treatment, while canagliflozin significantly increased high‐density lipoprotein cholesterol (HDL‐c) level and decreased plasma ANGPTL3 level. In addition, the expression of ANGPTL3 in liver tissues decreased obviously in diabetic mice with canagliflozin treatment. Conclusions. Canagliflozin increases HDL‐c level and suppresses ANGPTL3 expression in patients with T2DM and diabetic mice. The reduction of ANGPTL3 may contribute to the increase of HDL‐c. However, the specific mechanism needs further research. This trial is registered with ChiCTR1900021231.
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 2431441
Open AccessThe Effect of Canagliflozin on High‐Density Lipoprotein Cholesterol and Angiopoietin‐Like Protein 3 in Type 2 Diabetes Mellitus
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while the results remain controversial. This study is aimed at exploring the effect of SGLT2 inhibitor canagliflozin on lipid profile. Methods. This study was a single‐center, open‐label, nonrandomized, prospective study. Metformin (500 mg three times per day) or canagliflozin (100 mg, once daily) was administered for 12 weeks. Fasting blood samples were collected before and 12 weeks after treatment. Serum lipid profile levels and angiopoietin‐like protein 3 (ANGPTL3) were determined. In animal experiment, C57BL/6 J mice were divided into three groups including control, STZ + HFD, and STZ + HFD + canagliflozin. Lipid profile and plasma ANGPTL3 level were measured after 12 week’s treatment. Moreover, the expression of ANGPTL3 was detected in the liver tissues. Results. There was a decreased trend in low‐density lipoprotein cholesterol (LDL‐c) and triglycerides (TG) after canagliflozin treatment, while canagliflozin significantly increased high‐density lipoprotein cholesterol (HDL‐c) level and decreased plasma ANGPTL3 level. In addition, the expression of ANGPTL3 in liver tissues decreased obviously in diabetic mice with canagliflozin treatment. Conclusions. Canagliflozin increases HDL‐c level and suppresses ANGPTL3 expression in patients with T2DM and diabetic mice. The reduction of ANGPTL3 may contribute to the increase of HDL‐c. However, the specific mechanism needs further research. This trial is registered with ChiCTR1900021231.
- Open Access
- 22 December 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-7
Relationship of Para and Perirenal Fat and High-Density Lipoprotein and Its Function in Patients with Type 2 Diabetes Mellitus
Background. Para and perirenal fat is a fat pad surrounding the kidneys. Recent studies showed the association between para and perirenal fat and cardiovascular diseases including atherosclerosis and hypertension. We aimed to assess the relationship between para-perirenal ultrasonographic fat thickness and serum high-density lipoprotein (HDL) level and cholesterol efflux capacity of HDL in patients with type 2 diabetes mellitus (T2DM). Methods. We recruited 58 subjects with T2DM and collected anthropometric indices including height, weight, waist circumference, and other clinical data. Para-perirenal ultrasonographic fat thickness (PUFT) was measured via ultrasound. Serum lipid profile and other metabolic indices were determined as well. Correlation analysis and regression analysis were performed to analyze the relationship between PUFT and HDL level and cholesterol efflux capacity in all patients and subgroups. Results. Patients with higher PUFT have lower serum HDL level but increased cholesterol efflux capacity. Further analysis showed that PUFT negatively correlated with the serum HDL level in all patients, with no difference in groups divided by body mass index (BMI). In addition, PUFT was positively correlated with cholesterol efflux capacity in all patients. Multiple stepwise regression analysis showed an independent association of PUFT and serum HDL level and cholesterol efflux capacity. Conclusions. PUFT is closely correlated with the serum HDL level and cholesterol efflux capacity in patients with T2DM.
- 22 December 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-7
Open AccessRelationship of Para and Perirenal Fat and High-Density Lipoprotein and Its Function in Patients with Type 2 Diabetes Mellitus
Background. Para and perirenal fat is a fat pad surrounding the kidneys. Recent studies showed the association between para and perirenal fat and cardiovascular diseases including atherosclerosis and hypertension. We aimed to assess the relationship between para-perirenal ultrasonographic fat thickness and serum high-density lipoprotein (HDL) level and cholesterol efflux capacity of HDL in patients with type 2 diabetes mellitus (T2DM). Methods. We recruited 58 subjects with T2DM and collected anthropometric indices including height, weight, waist circumference, and other clinical data. Para-perirenal ultrasonographic fat thickness (PUFT) was measured via ultrasound. Serum lipid profile and other metabolic indices were determined as well. Correlation analysis and regression analysis were performed to analyze the relationship between PUFT and HDL level and cholesterol efflux capacity in all patients and subgroups. Results. Patients with higher PUFT have lower serum HDL level but increased cholesterol efflux capacity. Further analysis showed that PUFT negatively correlated with the serum HDL level in all patients, with no difference in groups divided by body mass index (BMI). In addition, PUFT was positively correlated with cholesterol efflux capacity in all patients. Multiple stepwise regression analysis showed an independent association of PUFT and serum HDL level and cholesterol efflux capacity. Conclusions. PUFT is closely correlated with the serum HDL level and cholesterol efflux capacity in patients with T2DM.